PD-L1 antibody [HL2985]

GeneTex

PD-L1 antibody [HL2985]

7

The Knockout validations were performed by both WB and ICC/IF assay. This antibody was raised against human PD-L1 Intracellular domain.

ICC/IF: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.

Flow Cytometry, ImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

Research Use Only

Monoclonal

HL2985

1 mg/ml

Unconjugated

CD274

CD274 molecule

B7 homolog 1; B7-H; B7H1; CD274 antigen; hPD-L1; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL1; PD-L1; programmed cell death 1 ligand 1

Rabbit

IgG

Programmed cell death 1 ligand 1

This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]

Human

-20°C or -80°C,2°C to 8°C

12352203